Efficacy of European marjoram essential oil on moderate depression

Evaluating of the clinical efficacy of European Origanum majorana L. essential oil in patients with moderate depression: a double-blind randomized clinical trial study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N240

Enrollment

Registered

2025-02-28

Start date

2025-03-10

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression. Major depressive disorder, single episode, unspecified

Interventions

Intervention 1: The intervention group will receive 20 mg/kg of standardized European marjoram essential oil every 12 hours and 50 mg of Asentra tablets. Intervention 2: The control group will receive

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent Over 18 years old People diagnosed with depression by a psychiatrist

Exclusion criteria

Exclusion criteria: History of mental illness History of antidepressant use History of thyroid disease and diseases that lead to depression A history of severe depression or suicidal thoughts History of underlying disease Experience of a traumatic event within the past 6 months

Design outcomes

Primary

Measure	Time frame
Depression score. Timepoint: Beginning of the study and end of the study. Method of measurement: Using the Beck Depression Inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hossein Rajaei

Kermanshah University of Medical Sciences

mhrajaee97@gmail.com+98 83 3427 6489

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026